Quebec Budget: Stability for Life Sciences, but Tax Concerns Loom

LAVAL, Quebec – March 19, 2026 – Quebec's government has tabled a budget that holds a steady course for its vital life sciences and health technologies (LSHT) sector, a move met with cautious approval from industry leaders who nonetheless harbor significant concerns about the real-world impact of recent tax reforms on innovation.

In its response to the 2026–2027 budget presented by Finance Minister Eric Girard, BIOQuébec, the association representing over 340 companies in the province's LSHT industry, acknowledged the government's prudence in maintaining its direction for the strategic sector. The budget aligns with the established priorities of the Quebec Life Sciences Strategy and the Quebec Research and Innovation Investment Strategy, reaffirming the industry's central role in the province's economic future.

However, the applause is tempered by a watchful vigilance. “In this pivotal political year and in a turbulent geopolitical context, the government must preserve its direction in innovation and in strategic sectors such as life sciences and health technologies. This budget, at the very least, maintains the course,” stated Benoît Larose, President and CEO of BIOQuébec.

This sentiment captures the core tension for the industry: while stability is welcome, the question remains whether simply 'maintaining the course' is sufficient to propel a sector that is a powerhouse of provincial research and development.

A Budget of Prudent Priorities

The 2026-2027 budget outlines nearly $9.6 billion in new measures over five years, framed against a challenging global economic backdrop. The government has earmarked over $1.7 billion to accelerate Quebec's economic transformation, with a significant portion aimed at fostering investment and competitiveness through innovation.

Specifically, the innovation ecosystem is set to receive $283 million over five years to support the entire innovation chain, from research to the adoption of cutting-edge technologies. This is complemented by an additional $45 million for university research and over $580 million dedicated to supporting small and medium-sized businesses (SMEs) across the province.

These investments are designed to buttress the government's ambitious, multi-year frameworks, including the 2022-2027 Québec Research and Innovation Investment Strategy (SQRI²), a $7.5 billion plan aimed at halving the labor productivity gap with Ontario, and the recently renewed Quebec Life Sciences Strategy 2025–2028, which is backed by nearly $271.5 million to stimulate industrial innovation and local production.

For an industry that contributes nearly $6.5 billion to Quebec's economy annually and accounts for 15.7% of all business R&D expenditures—almost triple that of the aerospace sector—this continued alignment is a positive signal. The budget demonstrates that the government recognizes the sector's strategic importance and is not deviating from its long-term vision.

The CRIC Conundrum: A Double-Edged Sword for Innovation

Despite the high-level strategic alignment, a significant point of friction persists in the form of a tax policy introduced in the previous budget. BIOQuébec remains deeply concerned about the refundable tax credit for research, innovation, and commercialization (CRIC), which took effect for fiscal years starting after March 25, 2025.

The CRIC was designed to simplify Quebec's complex web of R&D tax incentives, consolidating eight previous credits into a single, streamlined measure. Its goals were to enhance the basic credit rate, make pre-commercialization activities eligible, and refocus assistance on high-value jobs. However, the implementation has raised red flags for industry advocates.

A key point of contention is the CRIC's exclusion threshold, which requires companies to surpass a minimum spending level (starting at $50,000) before their R&D expenditures qualify for the credit. BIOQuébec argues this structure could have adverse effects on innovative SMEs and collaborative research projects, which are often the lifeblood of the LSHT ecosystem. For many startups and smaller research-intensive firms, whose financial runway is short and where every dollar counts, this threshold can represent a significant barrier to accessing crucial funding.

Critics within the industry describe the CRIC as a "one-size-fits-all" approach that fails to recognize the diverse business models and financial realities of innovative SMEs. While the reform aimed for simplification, it may have inadvertently weakened a critical financial lever for the very companies poised for high growth. The association has previously advocated for a more adaptable tax measure, better tailored to the unique needs of these agile, R&D-intensive companies.

Beyond the Balance Sheet: A New Vision for Public Contracts

Another significant development for the LSHT sector lies outside the budget's direct spending but is equally important for its future: the upcoming renewal of the Government Strategy for Public Procurement. For years, industry groups across Quebec have criticized the prevailing "lowest compliant price" model for awarding public contracts.

This approach, while intended to ensure fiscal prudence, has been widely criticized for sacrificing quality, discouraging innovation, and potentially leading to higher long-term costs. The risks of this model were notably highlighted by the Charbonneau Commission. In a sector like health technologies, where the value of a product extends far beyond its initial price tag to include efficacy, safety, and long-term patient outcomes, the lowest-bidder rule is particularly problematic.

BIOQuébec has signaled its intent to collaborate fully on the renewal, pushing for a model that prioritizes quality and value over the lowest price. This shift would encourage dialogue between government buyers and the business community, allowing for procurement decisions that factor in innovation, performance, and overall societal benefit.

A modernized procurement strategy that rewards value could act as a powerful economic lever, creating a robust local market for Quebec's own innovative medical technologies, diagnostic tools, and pharmaceuticals. It represents an opportunity to align the government's purchasing power with its industrial strategy, fostering a virtuous cycle of local innovation and adoption.

As the province moves forward, the LSHT industry finds itself at a crossroads. The government's budget provides a stable strategic foundation, continuing its commitment to a sector it rightly identifies as critical. Yet, the true measure of this support will be revealed in the details of implementation. The industry will be closely watching whether the CRIC can be adjusted to better support the small innovators it currently risks marginalizing, and whether the promised public procurement reform will truly usher in a new era of value-based decision-making. The answers to these questions will determine if Quebec can not only maintain its course but accelerate its journey to becoming a global leader in health innovation.